Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells $522,556.64 in Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 25,972 shares of the firm’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $20.12, for a total transaction of $522,556.64. Following the completion of the transaction, the chief executive officer directly owned 291,491 shares in the company, valued at approximately $5,864,798.92. This represents a 8.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Laura Francis also recently made the following trade(s):

• On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total transaction of $78,538.46.
• On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The shares were sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Stock Up 0.1%

SIBN stock opened at $19.21 on Friday. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. The firm has a 50-day moving average of $17.87 and a two-hundred day moving average of $15.45. SiBone has a 12 month low of $11.48 and a 12 month high of $21.89. The company has a market cap of $851.96 million, a price-to-earnings ratio of -56.50 and a beta of 0.66.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. As a group, analysts forecast that SiBone will post -0.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SIBN. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Truist Financial reaffirmed a “buy” rating and issued a $23.00 target price (up from $21.00) on shares of SiBone in a research note on Tuesday, August 4th. UBS Group lifted their price target on SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Finally, TD Cowen boosted their price target on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, SiBone currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.17.

Institutional Trading of SiBone

Several institutional investors have recently made changes to their positions in SIBN. First Light Asset Management LLC increased its stake in SiBone by 6.4% during the first quarter. First Light Asset Management LLC now owns 5,353,190 shares of the company’s stock worth $67,611,000 after acquiring an additional 320,286 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of SiBone by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 2,501,555 shares of the company’s stock valued at $49,331,000 after purchasing an additional 11,566 shares during the last quarter. Granahan Investment Management LLC lifted its stake in shares of SiBone by 97.6% in the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock valued at $21,965,000 after purchasing an additional 858,942 shares during the last quarter. Nuveen LLC lifted its stake in shares of SiBone by 5.1% in the 4th quarter. Nuveen LLC now owns 1,421,946 shares of the company’s stock valued at $28,041,000 after purchasing an additional 69,229 shares during the last quarter. Finally, Cadian Capital Management LP grew its holdings in shares of SiBone by 96.8% during the 4th quarter. Cadian Capital Management LP now owns 1,171,100 shares of the company’s stock worth $23,094,000 after purchasing an additional 576,100 shares during the period. Hedge funds and other institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.